Multi-Cancer Early Detection Screening Test

SOUL MINDED living believes that early intervention promotes health and longevity. Screening for cancer is a great way to remain proactive about your health.  While cancer can affect anyone at any stage of life, the risk significantly increases over the age of 50.  The current statistics suggest that approximately 40% of the population will receive a cancer diagnosis in their lifetime.  This equals roughly 1 in 2.5 people.  There are several chronic conditions and lifestyle factors that further increase cancer risk, particularly in those between ages 50-79 which include, but are not limited to:  alcohol use, smoking, diabetes, high BMI (>30), immune mediated diseases like asthma, and inflammatory bowel disease.  

TODAY, there are 5 recommended cancer screening tests that together only account for 1 in 4 diagnosed cancers in patients over 50 years of age.3,4  These include breast, cervical, lung, colorectal, and prostate cancer.  Roughly 3 out of 4 of cancer deaths are caused by cancers without recommended screening tests.5,6  The deadliest cancers for adults aged 65+ have no recommended screening tests.  These include pancreas, liver (and intrahepatic bile duct), leukemia, Non-Hodgkin lymphoma, bladder, and ovarian cancers.  Today, most cancers are diagnosed too late.  Finding cancer early is important to provide care when there may be more treatment options and potential for better outcomes.1  When cancers are diagnosed early before they have had a chance to spread, the overall 5-year survival rate is 4x higher than when diagnosed in later stages.1,7  The vast majority of cancers show no symptoms until later stages, when treatment options may be limited.2

FAMILY history of cancer in first-degree blood relatives can increase a patient’s risk of cancer.  Studies show that 93% of adults ages 50-79 with a family history of cancer would want to know if they have cancer as early as possible in order to take action12.  Many served as care givers to their loved ones and do not want to subscribe to the same fate.  Similarly, patients who have already suffered through cancer once are likely to have a recurrence.  Current statistics suggest that 1 in 5 patients ages 65 and older have survived cancer and face an elevated risk of developing and dying from a reoccurring cancer.

GALLERI testing, offered at Soul Minded, is the first of its kind multi-cancer early detection test that screens for a signal shared by multiple cancers, many without recommended screening tests. In a clinical study the test was able to detect a signal shared by more than 50 types of cancer with a simple blood draw.

ALL cells, including healthy and cancer cells, contain DNA. The DNA from cancer cells is different from the DNA of healthy cells. As cells grow through their lifecycle and die, DNA is released into the bloodstream. The Galleri test can tell the difference between DNA from cancer cells and DNA from healthy cells.  Galleri was trained using a database that contains DNA from thousands of different cancer patients and healthy patients. This training uses advanced technology that allows Galleri to identify a cancer signal and then predict where the cancer signal originated in the body.11

IT is important to know that Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.  The Galleri test is a simple blood draw, that looks for active cancer and does not predict your future genetic risk for cancer.  It should be used in addition to guideline recommended cancer screenings such as mammography, colonoscopy, PSA, or cervical cancer screening.  The Galleri test does not detect all cancers and not all cancers can be detected in the blood.  False positive and false negative results do occur.

TO learn more about the Galleri test at www.soulmindedhealth.com/galleri or watch a short video here.  Take control of your health by scheduling a FREE Discovery Call.

REFERENCES

1. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Research Data, Nov 2018 Submission. Includes persons aged 50-79 diagnosed 2006-2015 “Early/Localized” includes invasive localized tumors that have not spread beyond organ of origin, “Late/Metastasized” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.

2. Cancer Facts and Figures 2021 https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-factsand-figures-2021.pdf

3. Modeled detection extrapolated to 2020 US population ages 50–79

4. Hackshaw A, et al. Br J Cancer. 2021;125(10):1432-1442. DOI: 10.1038/s41416-021-01498-4. Data on file GA-2021-010. Calculated by internal analysis using data from SEER*Stat Database: Incidence which represents 34.6% of US population - SEER 18 Regs Research Data,

Nov 2018 Submission. Includes persons aged 50-79 diagnosed 2006-2015 and CCGA substudy 2 (methylation training and test) performance. Screening includes methods with United States Preventive Services Task Force (USPSTF) A, B, or C rating (breast, colon, cervical, prostate, and lung). Subject to important limitations, including the assumption that CCGA substudy 2 results are generalizable to a

real-world population similar to the Surveillance, Epidemiology, and End Results (SEER) registry.

5. Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years)

6. Estimated deaths per year in 2022 from American Cancer Society Cancer Facts and Figures 2022. Available at: http://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2022/cancer-facts-and-figures-2022.pdf. Data on file GA 2021-0065

7. Noone AM, Howlader N, Krapcho M, et al. (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER website April 2018.

8. Amin MB, et al. (Eds). American Joint Committee of Cancer (AJCC) Cancer Staging Manual (8th edition)

9. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. doi: 10.1016/j.annonc.2021.05.806.

10. Data source: U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on 2019 submission data

(1999-2017): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute;

www.cdc.gov/eancer/dataviz, released in June 2020.

11. Liu MC, Oxnard GR, Klein EA, et al. for CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation

signatures in cell-free DNA. Ann Oncol. 2020;31(6):745-759. doi: 10.1016/j.annonc.2020.02.011.

12.  [GRAIL, Inc. Data on file:GR-2024-0232] 

galleri.com/safety-information